The Biggest Canned Vegetable Recalls In US History
Canned vegetables are a convenient way to boost the nutritional content of a meal. Whether you're making pasta, a casserole, or chili, you can usually stir in some canned beans or peas with minimal effort. After all, the vegetables have usually been cooked and treated before they were canned.
But sometimes, things go wrong. In the past, people have opened their canned vegetables to discover foreign objects inside (including shards of glass), and other times, the seal has been broken or the cans have been swollen (likely due to the presence of harmful bacteria).
But don't panic about using your favorite canned vegetables, because usually, if a problem is discovered, products are recalled from the market very quickly. Often, they are pulled off the shelves before anyone can get sick or injured. If you want to learn more about the potential risks with canned vegetables, find some of the biggest recalls in history below. Spoiler alert: most of the recalls are to do with deadly bacteria.
Read more: Canned Corn Brands Ranked From Worst To Best
When you open a can of green beans, the last thing you want to find is a foreign object inside -- but it does happen. In March 2025, for example, Del Monte Foods had to recall more than 197,000 cans of cut green beans, sold under Target's Good & Gather brand, due to fears they had been contaminated with a foreign object. At the time of the recall, the cans of beans had already been sent to Target stores in more than 20 states across the U.S.
The type of object in the beans was unspecified, but some of the most common examples of contaminants found in food products include things like plastic fragments, glass, rocks, and shards of metal. They all pose a choking risk, and could even cause internal injuries, too. The Food and Drug Administration (FDA) classified the Del Monte Foods recall as Class II, which means that the foreign object could cause consumers to experience temporary consequences, or consequences that require medical intervention to resolve. It is a step down from a Class I recall, which means the FDA determines there is a reasonable chance that the product could cause serious health consequences.
In a bid to protect consumers from injuries or choking, anyone who had already purchased the green beans from Target was urged not to consume them. Target stores were also instructed not to distribute the product any longer.
If a can of food appears swollen or leaking, it's always best to discard it. This is because it could contain Clostridium botulinum, a neurotoxin that produces gas (hence the bloated can). If consumed, this bacteria can lead to a life-threatening disease called botulism. This is why, in 2024, Tradewind Foods recalled more than 31,000 pounds of Goya Red Kidney Beans from the market, after an inspection by the FDA found leaking, swollen cans in its warehouse. At the time of the recall, the cans had already been sent to stores across Puerto Rico and St. Croix.
Due to the dangers associated with Clostridium botulinum, this recall was also given Class II status by the FDA. Anyone who had already eaten the kidney beans was urged to contact a healthcare provider, as sometimes botulism symptoms (which include blurred vision, slurred speech, and trouble breathing) can be delayed.
It's important to note that while foodborne botulism is a serious disease that affects the brain, it is also very rare. In 2019, for example, there were 215 cases of botulism, and only 10% were caused by food products. Other types of botulism include wound (which often comes from infected cuts or needles) and infant (which can be related to consuming honey too young or even being around soil that is contaminated).
In 2024, foreign objects were the cause of another canned vegetable recall. In this case, Texas company M-C McLane International had to pull nearly 3,000 cases of canned jalapeños from stores in 28 states -- including Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho, and Illinois -- due to fears they had been contaminated with pieces of glass. As mentioned above, this is a serious health risk. Consuming glass by accident can lead to oral and dental injuries, and if swallowed, it can even cause internal cuts, too. If the cuts are serious, they could even require medical intervention.
A few brands have dealt with broken glass contamination in the past. A year before the M-C McLane recall, for example, grocery store chain Trader Joe's had to recall its Instant Cold Brew Coffee from the shelves due to fears it contained shards of broken glass.
Glass can get into cans of food due to broken pieces of equipment in the factory where they were processed. It can also be something as simple as a broken light or bottle, which scatters and leaves undetected shards in the food. Glass can be particularly hard to spot, given it is usually transparent. In a bid to protect consumers from injuries, anyone who had already purchased the recalled jalapeños was urged to either throw them away or return them to the store they bought them from for a refund.
Foodborne botulism might be rare, but it is still a major risk with many canned foods. This is because the bacteria that causes the disease, Clostridium botulinum, can only grow when there is very little oxygen. Canned foods are usually vacuum-sealed, which helps to keep out external contaminants.
To keep people safe from botulism, which, as mentioned earlier can be fatal, companies that produce canned foods have to act quickly when there is any sign of the potential for Clostridium botulinum growth. In April 2021, Faribault Foods issued a recall for S&W Organic Black Beans and O Organic Chili Beans from Costco stores in 11 states due to fears that the seals on the canned beans had been compromised.
The issue was actually brought to light by consumers who had already bought the beans and complained to Faribault Foods that the seal on the cans had failed. At first, only six products were recalled, all of which were distributed in 2021 but had best before dates in 2023. In the following May, however, the recall was updated to include 10 more products. Anyone who had already purchased any of the products on the recall list was urged not to consume them, and instead return them to the Costco store they bought them from for a full refund.
The 2025 recall wasn't a first for Del Monte Foods, which has long specialized in the production of canned fruits and vegetables. Back in 2018, it had to issue a recall for more than 64,200 cases of Fiesta Corn Seasoned With Red & Green Peppers due to concerns that the cans had not been processed thoroughly enough.
It turns out, in this particular case, there had been problems with the can sterilization process. This process is vital for consumer safety, as it involves treating food with high temperatures to kill potentially deadly pathogens. This also means that the food lasts longer, and can be safely stored outside of the refrigerator. Without this process, the contents of canned foods are left vulnerable to the growth of harmful bacteria, like Clostridium botulinum.
At the time of the Del Monte Foods recall, the canned corn had already been sent to 25 states, as well as 12 international locations, including Belize, Bermuda, El Salvador, Haiti, and Uruguay. Thankfully, despite the processing error, there were no reported incidents of botulism or any other illness associated with the recalled corn.
Just like with Faribault Foods, in 2017, Bush Brothers & Co. had to recall canned products from the market due to fears that the seals had been compromised. The company, which is known for its Bush's Best bean products, had to recall three types of beans from stores across the U.S. because of the default. These were: Brown Sugar Hickory, Country Style, and Original.
This time, the issue (thankfully) wasn't discovered by consumers, but by the company during internal quality checks. And fortunately, despite the fact that the beans had already been shipped out to stores nationwide, there were no reports of any illnesses associated with consuming the products. However, Bush Brothers & Co. didn't want to take any chances — again, anyone who had already purchased the beans was urged to dispose of them, even if they didn't look off or spoiled.
This is because botulism is not easy to spot. It doesn't have a distinct smell, for example, and you won't be able to see it or taste it either. Even eating a very small amount of contaminated food could lead to sickness. This is why if there is any doubt about botulism risk with canned food, the best course of action is to simply get rid of the food without consuming it.
Canned vegetables can be pulled from the shelves for many reasons. As we've seen already on this list, sometimes, it's because of foreign objects, and often, it's because of botulism fears. But another reason why companies issue recalls? Allergens. In fact, this is one of the most common reasons why any type of food product is recalled from stores and restaurants.
This is what happened in 2016, when Sager Creek Foods had to recall around 15,000 cases of canned beans and peas, including Allens Cut Green Beans, Monarch Mixed Cut Green Beans, and Allens Field Peas With Snaps, from the shelves. The company was concerned that the contents had been contaminated with shellfish, which is a common allergen in the U.S.
In fact, research suggests that roughly 2% of Americans have an allergy to shellfish. If any of those people consumed the beans, they might experience symptoms of an allergic reaction, even if it was only a trace amount. For some people, this reaction could even involve life-threatening anaphylaxis. At the time of the recall, the canned beans and peas had already been shipped to foodservice locations in 22 states. Fortunately, despite the risks, nobody reported allergic reactions as a result of consuming the recalled products.
Olives are a popular snack for many Americans. In fact, research suggests that more than half of the population enjoys munching on green olives. It makes sense, they're salty, briny, and nutritious, too. But one thing that is guaranteed to put you off your olives? That's the risk of botulism. As we've highlighted, this disease is very serious. It involves toxins, which attack the nervous system, and as a result, it can lead to paralysis and, in some rare cases, even death.
In 2013, Ocean State Job Lot, a Rhode Island-based grocery store chain, had to pull canned Mediterranean olives from the shelves in seven states, including New York, because they had been stored incorrectly. The olives, sold under the Bel Frantoio brand name, were supposed to be kept in the fridge, but instead they had been stored at room temperature. Storing canned goods like olives at cold temperatures is one way of reducing the risk of Clostridium botulinum growth.
Luckily, despite the mix-up with the storage temperatures, nobody reported any illnesses as a result of consuming the recalled olives. Anyone who had already bought the olives was urged not to eat them, and instead return them to Ocean State Job Lot for a refund.
As highlighted above, canned foods must be processed in a certain way to reduce the risk of harmful bacteria. They must be heat treated, for example, and sealed correctly, which reduces the risk of any external microorganisms contaminating the contents. But sometimes, canned vegetables are shipped out without the proper processing taking place, which puts consumers at risk of illness.
This was the case in 2011, when Wisconsin-based company Lakeside Foods had to recall around 3,000 cases of canned, pickled beets from foodservice locations in 18 states. The cans, which were sold under a range of brand names, including Monarch, Bountiful Harvest, and Lakeside, had been under-processed, which meant there was a risk of Clostridium botulinum growth. Fortunately, there were no incidents of botulism or any other foodborne illnesses related to the recalled beets. But once again, anyone who had already bought the product was urged not to consume it, even if the contents of the can looked and smelled normal. Instead, customers were urged to return any unopened cans back to Lakeside Foods.
Lakeside Foods has been caught up in recalls a few times with foodborne bacteria. In 2017, six years after the canned beets recall, it had to issue another recall for frozen peas due to Listeria concerns, for example. And in 2006, it also had to issue a recall of several latte products due to fears that the seal had leaked, allowing bacteria contamination.
In 1981, more than 5 million cans of mushrooms, all produced by Oxford Royal Mushrooms and sold under 45 different brands, were recalled from 30 states and the District of Columbia due to botulism fears. The issue was brought to light when a consumer, a fireman named Ron Hill who lived in Illinois, opened one of the cans and it exploded in his face. This was likely due to the build up of gas from Clostridium botulinum, and indeed, a test revealed the deadly bacteria was present in Hill's can.
The FDA acted quickly, instructing Oxford Royal Mushrooms to issue an urgent recall. A later investigation revealed that there had been processing errors at one of the company's packing plants. Thankfully, nearly all of the cans were pulled from the shelves promptly, and nobody reported any cases of foodborne botulism.
Botulism has long been an issue in the canned vegetable world. Before the mammoth 1981 recall, in the 1970s, brands were also pulling cans off the shelves due to fears around Clostridium botulinum. In 1973, for example, the Ohio-based United Canning Company of East Palestine recalled nearly 30,000 cans of mushrooms from several states, including New York, Pennsylvania, Wisconsin, and Illinois, after it discovered a swollen can in its warehouse. Further testing of the can revealed it did indeed contain Clostridium botulinum.
Because of the test results, all of the other cans of mushrooms were left in the warehouse, but fortunately, none of them tested positive for the life-threatening bacteria. In an abundance of caution, however, the canning company still issued the recall, as there was no guarantee that none of the cans that had already shipped out to cities across the U.S. didn't present a botulism risk.
The 1973 recall from the United Canning Company of East Palestine had a big impact on the food industry. Following the inspection and testing of its canned mushrooms, the FDA ordered further inspections of canned mushrooms in 4,000 warehouses across the country, which ultimately led to even more recalls. In fact, the amount of mushrooms recalled during this time in total was a whopping 75 million cans.
Read the original article on Mashed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
an hour ago
- Miami Herald
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation


Miami Herald
an hour ago
- Miami Herald
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion will focus on Jaguar's ongoing efforts to further its orphan disease development programs. Participation Instructions for Jaguar Health's Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series When: Tuesday, June 10, 2025 from 9:00 - 10:00 AM Eastern Where: Online (Click Here). The fireside chat will also be available for replay following the event. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners' spring 2025 Spotlight Series. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ SOURCE: Jaguar Health, Inc.

Miami Herald
an hour ago
- Miami Herald
JBA AI Earns FDA SaMD Recognition
A New Era of Accessible Health Monitoring GARDEN GROVE, CALIFORNIA / ACCESS Newswire / June 9, 2025 / JBA AI, the flagship health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, proudly announces several major global milestones in its mission to make preventive healthcare more accessible, intelligent, and affordable. JBA AI has been officially recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD). In addition, the platform has now received Class B Medical Device approval from Vietnam's Ministry of Health. These achievements affirm the platform's safety, clinical effectiveness, and international credibility. The JBA AI mobile application is already available globally for Android users and will soon be released on iOS. It enables contactless, non-invasive vital signs monitoring directly through smartphones or tablets. In just 60 seconds, the app delivers insights on over nine key health metrics. These include heart rate, heart rate variability, blood oxygen saturation, respiratory rate, stress index, and estimated glucose and blood pressure trends. This is achieved using AI-powered facial signal analysis through camera-based remote photoplethysmography technology. Expanding its impact even further, JBA AI has partnered with one of Vietnam's largest financial institutions, which serves more than 30 millions members. Together, they are preparing to launch JBA AI nationwide, making preventive health monitoring more accessible through a trusted and widespread digital network. "JBA AI is more than a health app - it's a certified medical device. Recognized by both the FDA and Vietnam's Ministry of Health," said Tracy Trang Nguyen, founder and CEO of JBA AI. "We're proud to deliver trusted, clinically guided tools for daily health monitoring worldwide." Nguyen is a Vietnamese American engineer and wellness industry leader who developed JBA AI after surviving cancer. Her personal health journey inspired her to combine advanced artificial intelligence with affordable wellness solutions. Under her leadership, JBA AI complements other products within the JBA Brands portfolio, such as GlucoTrojan, Joint Revive Fucoidan, and Vegan Collagen, to form a fully integrated health ecosystem. JBA AI is already gaining traction and is starting to expand into pharmacies, corporate wellness programs, public health campaigns, and family clinics across the United States, Vietnam, and other countries. The platform's franchise-ready model supports rapid local deployment while keeping costs low and impact high. It is designed to help people monitor their health in real-time, without the need for needles, wearable devices or clinic visits. JBA AI is currently welcoming franchisees, affiliates, and institutional partners to help bring this technology to communities around the world. Whether at home or in partnership with healthcare providers, JBA AI is redefining preventive care through data-driven technology and a compassionate approach to well-being. Contact Information Catherine Marino Marketing Managercat@ 714 903 1009 SOURCE: AQP One, Inc. press release